Nanotechnology Now

• About Us
  
  • Advertising
  • Our Mission
  • Our Team
  • Comments
  • Friends
  • Contact
• Nanotechnology
• News
  
  • Current News
  • Press Releases
  • Submit Press
  • Press kit
  • Interviews
• Columns
• Products
  
  • Our Products
  • Books
  • Featured Books
• Directories
  
  • Companies/Academic
  • Events
  • Glossary
  • Best Of
• Career Center
• Nano-Social Network
• Nano Consulting
• My Account

Home > News > pSivida Signs Licensing Agreement with Faber Research LLC

January 9th, 2007

pSivida Signs Licensing Agreement with Faber Research LLC

Abstract:
Global bio-nanotech company pSivida Limited (NASDAQ:PSDV)(ASX:PSD)(Xetra:PSI) today announced it has entered into a licensing agreement with US-based Faber Research LLC (Faber) to develop pSivida's proprietary Durasert™, Zanisert™ and Co-Drug™ drug delivery technologies for infectious diseases and diseases of the ear.

This announcement follows an announcement on December 26, 2006 that pSivida entered into an exclusive negotiation period with a major global pharmaceutical company to acquire a worldwide, royalty bearing license to make, use and sell products using pSivida's drug delivery technologies. The pharmaceutical company will make payments totalling US$990k (AU$1.3m) to pSivida for the right to exclusively negotiate a licensing agreement with the Company for a period of three months and to fund the cost of a preclinical study. The commencement of licensing negotiations follows a 12 month evaluation of pSivida's technologies by the large global pharmaceutical company.

Source:
businesswire.com

Bookmark:

Related News Press

Nanomedicine

Nanotechnology could help fight diabetes: Injectable nanogel can monitor blood-sugar levels and secrete insulin when needed May 16th, 2013

Nanobiotix Revenue for the 1st quarter of 2013 May 15th, 2013

Pitt Chemists Demonstrate Nanoscale Alloys So Bright They Could Have Potential Medical Applications: “Think about a particle that will not only help researchers detect cancer sooner but be used to treat the tumor, too.” May 15th, 2013

Using clay to grow bone: Researchers use synthetic silicate to stimulate stem cells into bone cells May 15th, 2013

Announcements

Kinks and curves at the nanoscale: New research shows 'perfect twin boundaries' are not so perfect May 20th, 2013

Aspen Aerogels Announces $22.5 Million Private Placement May 18th, 2013

NanoInk, Inc. Assets To Be Sold May 18th, 2013

Scientists capture first direct proof of Hofstadter butterfly effect May 17th, 2013